ABIOMED Stock News

The Impella heart pump from Abiomed treats edema or myocarditis, which can occur in COVID-19 patients.

The U.S. case tally for the coronavirus illness COVID-19 rose by fewer than 50,000 on Monday for a second straight day, data aggregated by Johns Hopkins...

The commercial rollout of ABIOMED's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.

Abiomed (ABMD) has announced that the US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading a

U.S. stock futures traded slightly lower on Tuesday as Wall Street took a breather following sharp gains in the previous session.

Medical device maker Abiomed Inc said on Tuesday the U.S. Food and Drug Administration granted its left-sided heart pumps emergency use authorization to help patients suffering from COVID-19-related h

The coronavirus has infected more than 18.5 million people around the world as of Wednesday, killing at least 701,085 people.

Shares of Abiomed Inc. undefined rallied 2.0% in premarket trading on Tuesday after the company said its Impella heart pump had received an emergency use...

Shares of Abiomed Inc. rallied 2.0% in premarket trading on Tuesday after the company said its Impella heart pump had received an emergency use authorization from the Food and Drug Administration as

The Food and Drug Administration has approved the emergency use of Abiomed's Impella heart pump for Covid-19 patients with heart failure.

The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 pa

Zurcher Kantonalbank Zurich Cantonalbank cut its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 30.2% during the second quarter, according to its most recent Form 13F filing with the Securities and

Janney Montgomery Scott LLC cut its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 3.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange

The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide lef

Eine dreijährige, von Prüfern geleitete prospektive Studie an japanischen Patienten mit einer Impella Herzpumpe stellte beim Einsatz von Impella bei P